The absorption of orally administered polyethylene glycol (PEG) has been used to assess intestinal permeability.
Indexing Terms: intestinal permeability/chromatography, liquid
The permeability of the intestinal mucosa to molecules varies with molecular size; hence, substances of different molecular sizes such as xylose (1), lactulose (2, 3), inulin (4), urea (5), creatinine (6) , mannitol (2, 6), EDTA (7), and polyethylene glycol (PEG) (8) have been used in tests of mucosal integrity under various physiological and pathological conditions (9-11 )4 Cellar disease is especially interesting because it is common (0.03% of the white population) (12), and a diagnostic laboratory test could obviate the need for biopsy. We used PEG because it has a low oral toxicity [although topical toxicity is well documented (13)], is not degraded by intestinal flora, is easily quantifiable in urine, and >90% of the dose administered is excreted in urine within 6 h after administration.
Moreover, the distribution of the various homologs in urine may differentiate healthy subjects and patients. We chose a low-molecular-mass PEG, PEG 400, for the present studies because the distribution of the various oligomers and their chromatographic resolution combine to make its analysis notably easier than that of heavier PEGs.
In this study we focused on (a) the validation of HPLC determination of PEG 400 in urine, (b) the study of urinary excretion of PEG 400 in healthy subjects to determine the importance of the intersubject variability 'Departamento 
Materials and Methods

Sample Treatment
To were used as the extraction solid phase, and 5 mL of each urine sample was diluted with 10 mL of water and 5 mL of methanol.
The whole volume (20 mL) was then added to the column and eluted with chloroform; the eluate was evaporated at 30#{176}C in a nitrogen atmosphere and the dry residues of the calibrators were dissolved at 37#{176}C in 5 mL of the mobile phase. The dry residues of the unknown samples were appropriately diluted to obtain concentrations within the calibration range. The samples to be analyzed were filtered with 0.45-pm (pore size) filters (Miffipore Waters Chromatography, Milford, MA). 
Analytical Method
Urinary Excretion of PEG 400
Three groups of subjects were used. The procedures followed were in accordance with the ethical standards of our institution's responsible committee and with the Helsinki The volunteers received a medical checkup, and gave written consent to their participation in the study. They were given a single dose of 10 gof PEG 400 in 100 mL of water after a 12-h fast. A cross-assay (2 x 2 Latin square) was used, whereby the six subjects were divided into two groups of three each. The first group fasted before and during the assay, whereas the second took PEG 400 with a continental breakfast.
Liquid was not restricted in either of the groups.
After 1 week the assay was repeated with the conditions interchanged.
In both cases the urine samples were collected 1, 2, 4, and 6 h after administration.
Group II: celiac patients on a gluten-free diet. This group included five children with celiac disease (four girls and one boy, 2-14 years old, 9-62 kg) who were in the second diagnostic phase of their illness and who had been on a gluten-free diet for 2 years. Permission for their participation in the study was granted by their parents.
To obtain the samples of intestinal mucosa we used a pediatric Kilby capsule for intestinal biopsy, introduced via mouth or nose. From the biopsy data, celiac subjects on a gluten-free diet showed normal intestinal viii except for two subjects who exhibited slight partial atrophy.
All the children received PEG 400 (0.175 g/kg body weight) diluted in 100 mL of water after a 12-h fast. Urine was collected during the 6 h after administration.
Group III: celiac patients. This group consisted of 16 children (eight girls and eight boys, 1-17 years of age, 9-61 kg) who were in the first stage of celiac disease and hence were on a diet in which gluten was still present. The permeabifity test was performed exactly as above. The celiac patients showed subtotal intestinal atrophy, except for two who showed moderate partial atrophy.
Results and DIscussIon
As a preliminary step to the study of urinary PEG excretion, the chosen analytical method was validated both in the mobile phase, with no impurities that might affect determination, and in urine. The separation of PEG 400 by HPLC resolved several peaks corresponding to the various oligomers Of Mr 282-634. To quantify PEG 400 we used the total area of all peaks. The percentage of the total area for individual peaks allowed estimation of the distribution of the oligomers. Up to eight PEG oligomers could be resolved (Fig. 1) The experimental design used to carry out the assay was a 2 x 2 Latin square. The statistical model took the following form:
where uk was the observation made of the ith individual during the jth period and in the kth test; j.t, overall mean; a, effect due to the ith individual; , effect due to the jth period; Tk, effect due to the kth assay; and e, random error normally distributed with zero mean and cr2 variance.
We measured the total PEG excreted (X) in 6 h and the ratio C of the four smallest oligomers to the three largest oligomers (expressed as mean percentages). The experimental design enabled us to carry out a three-way analysis of variance (ANOVA) for the selected variables. Table 1 shows the findings for each subject. Independent of the response used, the ANOVA results, taking as response X,, and the ratio C, showed that the intersubject variability was not significant gastric emptying primarily influences the oligomeric profile of PEG 400 in urine when C is used (P = 0.0175), so we confined ourselves to using the data of the fasting control subjects for later contrast with the other groups. Figure 3 shows the oligomeric profile for the selected control subjects (fasting) at each interval of urine collection. The proffle is completely unaltered throughout the collection period, so the test may be simplified as far as collection times are concerned; in principle, a urine collection period of 1 h would enable us to obtain the same results when interpreting the oligomeric profile. The results of the test carried out on the other groups are given in Table 2 . In agreement with the results obtained by Lifschitz et al. (18) , the celiac patients show an important reduction in X.
The differences among the three groups are evident from the mean oligomeric profiles in urine for each group (Fig. 4) difference between groups I and II is not significant; it is our opinion that the control group used for contrast with celiac patients could be composed exclusively of subjects consuming no gluten, with these subjects serving as their own controls in future comparisons, when gluten might be reintroduced into their diet. This would require that the number of subjects in this group be in- 
where Y is the jth observation of the ith subject, is the overall mean, a.t, is the effect of the ith treatment, and eij is. the random error normally distributed with zero mean and o variance. The ANOVA results for X, and quotient C showed that there are significant differences (a = 0.05, P = 0.0022 and 0.0002, respectively) among the three groups. This enabled us to apply Scheff#{233}'s test to contrast pairs of means ( Table 3 ) and consequently to determine which groups of subjects differed from each other.
From this comparison, the use of X and quotient C equally allows differentiation between normal subjects (group I) and celiac patients (group Ill), and between celiac patients and those with the gluten eliminated from their diet for 2 years (group II).
The results of the test also allow us to infer that the 1574 CLINICALCHEMISTRY, Vol.40, No.8, 1994 
b.C,d
Means of X and C for groups I, II, and Ill, respectively.
